Journal of robotic surgery · 2026
KangDuo surgical robot KD-SR-01 versus da Vinci Xi in robot-assisted colorectal cancer resection: oncologic outcomes at three years in a multicenter randomized trial.
СтатьяМногоцентровое исследованиеРандомизированное исследованиеСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cen Zhanpeng, Sun Zhen, Ma Tianyi, Du Donglin, Xu Lai, Lu Junyang, Wei Zhengqiang, Wang Guiyu, Xiao Yi
Аннотация
BACKGROUND: Earlier results from a multicenter randomized trial showed that colorectal cancer resection with KangDuo surgical robot KD-SR-01 (KD) and da Vinci Xi (DV) had similar perioperative and pathological outcomes, whereas long-term oncologic outcomes remained uncertain.
METHODS: Three-year follow-up data were analyzed for the full 100-patient cohort of the multicenter randomized trial (KD, n = 50; DV, n = 50). The long-term endpoints were disease-free survival (DFS) and overall survival (OS).
RESULTS: Median follow-up in both groups was 37 months (interquartile range [IQR], 34-40). Kaplan-Meier-estimated 3-year DFS rates were 85.3% for KD (95% confidence interval [CI], 71.5%-92.7%) and 85.5% for DV (95% CI, 71.9%-92.8%, log-rank P = 0.995). Kaplan-Meier-estimated 3-year OS rates were 100.0% for KD (95% CI, 100.0%-100.0%) and 94.0% for DV (95% CI, 82.4%-98.0%, log-rank P = 0.606). After covariate adjustment, the DFS hazard ratio (HR) comparing KD with DV was 0.918 (95% CI, 0.301-2.798; P = 0.881).
CONCLUSIONS: At 3 years, no significant between-group differences in DFS or OS were detected between patients assigned to KD-SR-01 and da Vinci Xi for colorectal cancer resection.
METHODS: Three-year follow-up data were analyzed for the full 100-patient cohort of the multicenter randomized trial (KD, n = 50; DV, n = 50). The long-term endpoints were disease-free survival (DFS) and overall survival (OS).
RESULTS: Median follow-up in both groups was 37 months (interquartile range [IQR], 34-40). Kaplan-Meier-estimated 3-year DFS rates were 85.3% for KD (95% confidence interval [CI], 71.5%-92.7%) and 85.5% for DV (95% CI, 71.9%-92.8%, log-rank P = 0.995). Kaplan-Meier-estimated 3-year OS rates were 100.0% for KD (95% CI, 100.0%-100.0%) and 94.0% for DV (95% CI, 82.4%-98.0%, log-rank P = 0.606). After covariate adjustment, the DFS hazard ratio (HR) comparing KD with DV was 0.918 (95% CI, 0.301-2.798; P = 0.881).
CONCLUSIONS: At 3 years, no significant between-group differences in DFS or OS were detected between patients assigned to KD-SR-01 and da Vinci Xi for colorectal cancer resection.